Lipitor
Teva launches first generic Lipitor in UK
May 8, 2012Sales and Marketing Lipitor, NHS, Pfizer, Teva, atorvastatin
Teva has launched the first generic Lipitor in the UK on the day the drug loses its patent protection. The …
Lipitor losses hit Pfizer
May 2, 2012Sales and Marketing Alzheimer's, Lipitor, Pfizer, patent expiry
Lipitor’s US patent expiry has inflicted heavy damage on Pfizer’s revenues, with global sales down 7% in the first three …
Pfizer sells nutrition business to Nestlé for $11.9 billion
April 23, 2012Business Services, Sales and Marketing Business, Lipitor, Pfizer, nestle, nutrition
Pfizer has sold its nutrition business to Nestlé for $11.85 billion in cash. Pfizer Nutrition is a leading global pediatric …
Sanofi sets up cholesterol drug showdown with Amgen
March 27, 2012Research and Development, Sales and Marketing Amgen, BMS, LDL, Lipitor, Merck, Regeneron, Sanofi
Sanofi and Amgen have posted results for their new injectable cholesterol drugs within 24 hours of each other. Both drugs …
Ranbaxy launches generic Lipitor in Europe
March 6, 2012Research and Development, Sales and Marketing Lipitor, Pfizer, Ranbaxy, atorvastatin, generics
Ranbaxy has launched its generic version of Pfizer’s Lipitor in Europe, months ahead of its May expiration date. The Indian …
Keep prescribing Lipitor – the generics are nearly here, says Pfizer
January 5, 2012Medical Communications, Sales and Marketing Lipitor, NHS, Pfizer, statin prescribing
Pfizer has launched a campaign to persuade UK doctors to keep prescribing Lipitor ahead of its patent expiry in May. …
Teva gains tentative approval to sell generic Lipitor in 2012
December 5, 2011Sales and Marketing Lipitor, Pfizer, Ranbaxy, Teva
Teva has gained a tentative approval by the FDA to sell its generic form of Pfizer’s blockbuster statin Lipitor next …
FDA approves Ranbaxy’s generic Lipitor
December 1, 2011Manufacturing and Production, Sales and Marketing Lipitor, Pfizer, Ranbaxy, Teva
The FDA will allow Ranbaxy to develop a generic version of Pfizer’s blockbuster statin Lipitor. The firm has received final …
Watson launches first generic Lipitor in US
November 30, 2011Sales and Marketing Lipitor, Pfizer, Watson, atorvastin
Watson Pharmaceuticals has launched its generic version of Pfizer’s blockbuster statin Lipitor as the drug goes off patent in the …
The changing of the guard – Q3 round up
November 25, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Lipitor, Q3, Ranbaxy
PfizerOf all the patent cliffs in pharma, Lipitor’s expiry represents the biggest. Pfizer is now staring over the precipice, with …
Pfizer hatches mail order plan for Lipitor
November 23, 2011Sales and Marketing Lipitor, Pfizer, US, generics
Pfizer is preparing to launch a new mail order service offering cut-price Lipitor direct to patients in the US.The firm …
Ranbaxy to collaborate with Teva on generic Lipitor in US?
November 7, 2011Manufacturing and Production, Sales and Marketing Lipitor, Pfizer, Ranbaxy, Teva
Israeli drugmaker Teva Pharmaceutical could get an unexpected boost from an earlier-than-expected launch of its generic version of Pfizer’s cholesterol …
Prevnar and Lyrica lift Pfizer results
November 1, 2011Research and Development, Sales and Marketing Lipitor, Lyrica, Pfizer, Prevnar, patent expiry
Strong sales of Lyrica and its Prevnar vaccines coupled with favourable exchange rates have helped Pfizer deliver a strong quarter. …
Crestor fails head-to-head test against Lipitor
September 2, 2011Sales and Marketing Crestor, Lipitor
AstraZeneca’s cholesterol drug Crestor has failed to show it can stop artery disease better than Pfizer’s Lipitor. The new study …
Pfizer’s ageing blockbuster Lipitor wins $770m paediatric boost
July 11, 2011Sales and Marketing Lipitor, Pfizer, paediatric trials
Pfizer has been given more time to sell its anti-cholesterol treatment Lipitor exclusively in Europe as a quid pro quo …
Latest content
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?
